KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables - Net: 2020-2024

Historic Receivables - Net for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $33.6 million.

  • AbCellera Biologics' Receivables - Net rose 127.10% to $71.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.2 million, marking a year-over-year increase of 127.10%. This contributed to the annual value of $33.6 million for FY2024, which is 9.89% up from last year.
  • As of FY2024, AbCellera Biologics' Receivables - Net stood at $33.6 million, which was up 9.89% from $30.6 million recorded in FY2023.
  • AbCellera Biologics' Receivables - Net's 5-year high stood at $213.2 million during FY2020, with a 5-year trough of $30.6 million in FY2023.
  • In the last 3 years, AbCellera Biologics' Receivables - Net had a median value of $33.6 million in 2024 and averaged $34.3 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first slumped by 75.97% in 2022, then climbed by 9.89% in 2024.
  • Yearly analysis of 5 years shows AbCellera Biologics' Receivables - Net stood at $213.2 million in 2020, then declined by 24.70% to $160.6 million in 2021, then crashed by 75.97% to $38.6 million in 2022, then dropped by 20.74% to $30.6 million in 2023, then climbed by 9.89% to $33.6 million in 2024.